Journal
ARTHRITIS RESEARCH & THERAPY
Volume 12, Issue 1, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/ar2905
Keywords
-
Categories
Funding
- CONACyT-SEP Ciencia Basica [51353]
- Universidad de Guadalajara agreement [25473]
- Lupus Foundation of America, Inc
- National Institutes of Health [AI47859]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI047859, R01AI047859] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Introduction: Autoantibodies to RNA helicase A (RHA) were reported as a new serological marker of systemic lupus erythematosus (SLE) associated with early stage of the disease. Anti-RHA and other autoantibodies in Mexican SLE patients and their correlation with clinical and immunological features were examined. Methods: Autoantibodies in sera from 62 Mexican SLE patients were tested by immunoprecipitation of S-35-labeled K562 cell extract and enzyme-linked immunosorbent assay (anti-U1RNP/Sm, ribosomal P, beta 2GPI, and dsDNA). Anti-RHA was screened based on the immunoprecipitation of the 140-kDa protein, the identity of which was verified by Western blot using rabbit anti-RHA serum. Clinical and immunological characteristics of anti-RHA-positive patients were analyzed. Results: Anti-RHA was detected in 23% (14/62) of patients, a prevalence higher than that of anti-Sm (13%, 8/62). Prevalence and levels of various autoantibodies were not clearly different between anti-RHA (+) vs. (-) cases, although there was a trend of higher levels of anti-RHA antibodies in patients without anti-U1RNP/Sm (P = 0.07). Both anti-RHA and -Sm were common in cases within one year of diagnosis; however, the prevalence and levels of anti-RHA in patients years after diagnosis did not reduce dramatically, unlike a previous report in American patients. This suggests that the high prevalence of anti-RHA in Mexican patients may be due to relatively stable production of anti-RHA. Conclusions: Anti-RHA was detected at high prevalence in Mexican SLE patients. Detection of anti-RHA in races in which anti-Sm is not common should be clinically useful. Racial difference in the clinical significance of anti-RHA should be clarified in future studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available